Harel Insurance Investments & Financial Services Ltd. Has $5.28 Million Holdings in Cencora, Inc. $COR

Harel Insurance Investments & Financial Services Ltd. lessened its holdings in Cencora, Inc. (NYSE:COR) by 11.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,911 shares of the company’s stock after selling 2,105 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Cencora were worth $5,278,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in COR. Vanguard Group Inc. lifted its position in Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after acquiring an additional 284,229 shares in the last quarter. Norges Bank acquired a new stake in shares of Cencora in the second quarter valued at about $695,215,000. Viking Global Investors LP increased its position in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the last quarter. Finally, Amundi raised its holdings in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after acquiring an additional 249,742 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the completion of the transaction, the chief executive officer owned 68,059 shares in the company, valued at $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,317 shares of company stock valued at $7,009,260. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on COR. Bank of America decreased their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. TD Cowen increased their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $381.42.

Cencora Stock Performance

NYSE COR opened at $354.96 on Friday. The stock has a market cap of $68.86 billion, a PE ratio of 44.65, a P/E/G ratio of 1.69 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The firm has a 50-day moving average of $349.64 and a 200-day moving average of $320.12. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.